Citi Reaffirms Bullish Stance on Apollo Hospitals: Target Price Set at ₹9,600

Market snapshot: Global brokerage Citi has maintained its 'Buy' rating on Apollo Hospitals (APOLLOHOSP), raising its target price to ₹9,600. The optimism stems from resilient operational metrics, the strategic inclusion of the stock in Citi’s Pan-Asia Focus List, and a clear roadmap for the digital segment to achieve profitability by Q1FY27.

Summary: Apollo Hospitals is poised for a valuation re-rating as its digital arm, Apollo 24/7, nears breakeven. With strong pricing power to offset inflation and limited exposure to Middle East volatility, the company remains a top pick in the healthcare sector.

Key Takeaways

• Target Price of ₹9,600 implies a potential upside of approximately 33-34% from current market levels.
• Apollo 24/7 digital platform is on track to hit EBITDA breakeven by Q1FY27, significantly reducing cash burn.
• Hospital segment continues to demonstrate strong pricing power, effectively passing through consumable inflation to maintain margins at 24.8%.

SAHI Perspective

Apollo is successfully transitioning from a traditional hospital chain to an integrated healthcare ecosystem. The narrowing losses in HealthCo, combined with aggressive bed capacity expansion (3,660 beds over 5 years), suggest that the current valuation discount relative to peers is narrowing. We view the 'Hospital of the Future' initiative in Hyderabad as a long-term differentiator in high-complexity care.

Closing Insight

As digital assets turn profitable and core hospital EBITDA grows at a projected 23% CAGR (FY25-28), Apollo Hospitals presents a compelling risk-reward profile for long-term investors.

High Performance Trading with SAHI.